TRVI

Trevi Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1563880Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(43.0M)

EPS (Basic, as reported)

$-0.32

Net Margin FY2025

—

ROE FY2025

-23.3%

Total Equity

$183.0M

Shares Out

142M

Business description

Trevi Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (21) → (43)

Fiscal yearFY2018FY2019FY2020FY2021⚑FY2022⚑FY2023FY2024FY2025

Research & development(14)(19)(22)(23)(20)(24)(39)(33)

General & administrative(4)(7)(10)(9)(10)(10)(12)(16)

Total operating expenses(18)(27)(32)(32)(30)(34)(52)(49)

Operating income(18)(27)(32)(32)(30)(34)(52)(49)

Interest expense0—0(1)(1)000

Interest & investment income—————547

Other income (expense), net(2)10(1)1547

Pre-tax income(21)(26)(33)(34)(29)(29)(48)(43)

Income tax expense00000000

Net income(21)(26)(33)(34)(29)(29)(48)(43)

EPS — basic———($1.49)($0.45)($0.29)($0.47)($0.32)

EPS — diluted———($1.49)($0.45)($0.29)($0.47)($0.32)

Shares outstanding — basic (M)———236599102135

Shares outstanding — diluted (M)———236599102135

⚑ Weighted-average shares changed ×2.83 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.52 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.